Shekswess/llama3_medquad_instruct_dataset huggingface dataset:
Question: What is the outlook for Male Breast Cancer ?
Answer: Survival for men with breast cancer is similar to survival for women with breast cancer.
                    Survival for men with breast cancer is similar to that for women with breast cancer when their stage at diagnosis is the same. Breast cancer in men, however, is often diagnosed at a later stage. Cancer found at a later stage may be less likely to be cured.
                
                
                    Certain factors affect prognosis (chance of recovery) and treatment options.
                    The prognosis (chance of recovery) and treatment options depend on the following:         - The stage of the cancer (whether it is in the breast only or has spread to other places in the body).    - The type of breast cancer.    - Estrogen-receptor and progesterone-receptor levels in the tumor tissue.    - Whether the cancer is also found in the other breast.    - The patients age and general health.
Question: What is (are) Primary Myelofibrosis ?
Answer: Key Points
                    - Primary myelofibrosis is a disease in which abnormal blood cells and fibers build up inside the bone marrow.    - Symptoms of primary myelofibrosis include pain below the ribs on the left side and feeling very tired.    - Certain factors affect prognosis (chance of recovery) and treatment options for primary myelofibrosis.
                
                
                    Primary myelofibrosis is a disease in which abnormal blood cells and fibers build up inside the bone marrow.
                    The bone marrow is made of tissues that make blood cells (red blood cells, white blood cells, and platelets) and a web of fibers that support the blood-forming tissues. In primary myelofibrosis (also called chronic idiopathic myelofibrosis), large numbers of blood stem cells become blood cells that do not mature properly (blasts). The web of fibers inside the bone marrow also becomes very thick (like scar tissue) and slows the blood-forming tissues ability to make blood cells. This causes the blood-forming tissues to make fewer and fewer blood cells. In order to make up for the low number of blood cells made in the bone marrow, the liver and spleen begin to make the blood cells.
Question: What is (are) Urethral Cancer ?
Answer: Key Points
                    - Urethral cancer is a disease in which malignant (cancer) cells form in the tissues of the urethra.    - There are different types of urethral cancer that begin in cells that line the urethra.     - A history of bladder cancer can affect the risk of urethral cancer.    - Signs of urethral cancer include bleeding or trouble with urination.     - Tests that examine the urethra and bladder are used to detect (find) and diagnose urethral cancer.    - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Urethral cancer is a disease in which malignant (cancer) cells form in the tissues of the urethra.
                    The urethra is the tube that carries urine from the bladder to outside the body. In women, the urethra is about 1 inches long and is just above the vagina. In men, the urethra is about 8 inches long, and goes through the prostate gland and the penis to the outside of the body. In men, the urethra also carries semen.     Urethral cancer is a rare cancer that occurs more often in men than in women.
                
                
                    There are different types of urethral cancer that begin in cells that line the urethra.
                    These cancers are named for the types of cells that become malignant (cancer):         -  Squamous cell carcinoma is the most common type of urethral cancer. It forms in cells in the part of the urethra near the bladder in women, and in the lining of the urethra in the penis in men.    -  Transitional cell carcinoma forms in the area near the urethral opening in women, and in the part of the urethra that goes through the prostate gland in men.    -  Adenocarcinoma forms in the glands that are around the urethra in both men and women.         Urethral cancer can metastasize (spread) quickly to tissues around the urethra and is often found in nearby lymph nodes by the time it is diagnosed.
                
                
                    A history of bladder cancer can affect the risk of urethral cancer.
                    Anything that increases your chance of getting a disease is called a risk factor. Having a risk factor does not mean that you will get cancer; not having risk factors doesnt mean that you will not get cancer. Talk with your doctor if you think you may be at risk. Risk factors for urethral cancer include the following:         - Having a history of bladder cancer.     - Having conditions that cause chronic inflammation in the urethra, including:               - Sexually transmitted diseases (STDs), including human papillomavirus (HPV), especially HPV type 16.      - Frequent urinary tract infections (UTIs).
Question: what research (or clinical trials) is being done for Urethral Cancer ?
Answer: New types of treatment are being tested in clinical trials.
                    Information about clinical trials is available from the NCI website.
                
                
                    Patients may want to think about taking part in a clinical trial.
                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
                
                
                    Patients can enter clinical trials before, during, or after starting their cancer treatment.
                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
Question: what research (or clinical trials) is being done for Melanoma ?
Answer: New types of treatment are being tested in clinical trials.
                    Information about clinical trials is available from the NCI website
                
                
                    Treatment for melanoma may cause side effects.
                    For information about side effects caused by treatment for cancer, see our Side Effects page.
                
                
                    Patients may want to think about taking part in a clinical trial.
                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
                
                
                    Patients can enter clinical trials before, during, or after starting their cancer treatment.
                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
                
                
                    Follow-up tests may be needed.
                    Some of the tests that were done to diagnose the cancer or to find out the stage of the cancer may be repeated. Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.   Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back). These tests are sometimes called follow-up tests or check-ups.
Question: What is (are) Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor ?
Answer: Key Points
                    - Central nervous system atypical teratoid/rhabdoid tumor is a disease in which malignant (cancer) cells form in the tissues of the brain.    - Certain genetic changes may increase the risk of atypical teratoid/rhabdoid tumor.    - The signs and symptoms of atypical teratoid/rhabdoid tumor are not the same in every patient.    - Tests that examine the brain and spinal cord are used to detect (find) CNS atypical teratoid/rhabdoid tumor.    - Childhood atypical teratoid/rhabdoid tumor is diagnosed and may be removed in surgery.    - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Central nervous system atypical teratoid/rhabdoid tumor is a disease in which malignant (cancer) cells form in the tissues of the brain.
                    Central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT) is a very rare, fast-growing tumor of the brain and spinal cord. It usually occurs in children aged three years and younger, although it can occur in older children and adults.    About half of these tumors form in the cerebellum or brain stem. The cerebellum is the part of the brain that controls movement, balance, and posture. The brain stem controls breathing, heart rate, and the nerves and muscles used in seeing, hearing, walking, talking, and eating. AT/RT may also be found in other parts of the central nervous system (brain and spinal cord).    This summary describes the treatment of primary brain tumors (tumors that begin in the brain). Treatment for metastatic brain tumors, which are tumors formed by cancer cells that begin in other parts of the body and spread to the brain, is not covered in this summary. For more information, see the PDQ summary on Childhood Brain and Spinal Cord Tumors Treatment Overview about the different types of childhood brain and spinal cord tumors.   Brain tumors can occur in both children and adults; however, treatment for children may be different than treatment for adults. See the PDQ treatment summary on Adult Central Nervous System Tumors Treatment for more information.
Question: How to diagnose Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor ?
Answer: Tests that examine the brain and spinal cord are used to detect (find) CNS atypical teratoid/rhabdoid tumor. The following tests and procedures may be used:         -   Physical exam and history : An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient's health habits and past illnesses and treatments will also be taken.    -   Neurological exam : A series of questions and tests to check the brain, spinal cord, and nerve function. The exam checks a persons mental status, coordination, and ability to walk normally, and how well the muscles, senses, and reflexes work. This may also be called a neuro exam or a neurologic exam.     -   MRI (magnetic resonance imaging): A procedure that uses a magnet, radio waves, and a computer to make a series of detailed pictures of areas inside the brain and spinal cord. This procedure is also called nuclear magnetic resonance imaging (NMRI).    -   Lumbar puncture : A procedure used to collect cerebrospinal fluid (CSF) from the spinal column. This is done by placing a needle between two bones in the spine and into the CSF around the spinal cord and removing a sample of fluid. The sample of CSF is checked under a microscope for signs of tumor cells. The sample may also be checked for the amounts of protein and glucose. A higher than normal amount of protein or lower than normal amount of glucose may be a sign of a tumor. This procedure is also called an LP or spinal tap.    -   SMARCB1 and SMARCA4 gene testing: A laboratory test in which a sample of blood or tissue is tested for the SMARCB1 and SMARCA4 genes.
                    Childhood atypical teratoid/rhabdoid tumor is diagnosed and may be removed in surgery. If doctors think there might be a brain tumor, a biopsy may be done to remove a sample of tissue. For tumors in the brain, the biopsy is done by removing part of the skull and using a needle to remove a sample of tissue. A pathologist views the tissue under a microscope to look for cancer cells. If cancer cells are found, the doctor may remove as much tumor as safely possible during the same surgery. The pathologist checks the cancer cells to find out the type of brain tumor. It is often difficult to completely remove AT/RT because of where the tumor is in the brain and because it may already have spread at the time of diagnosis.      The following test may be done on the sample of tissue that is removed:         -   Immunohistochemistry : A test that uses antibodies to check for certain antigens in a sample of tissue. The antibody is usually linked to a radioactive substance or a dye that causes the tissue to light up under a microscope. This test is used to tell the difference between AT/RT and other brain tumors.
Question: What are the stages of Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor ?
Answer: Key Points
                    - There is no standard staging system for central nervous system atypical teratoid/rhabdoid tumor.
                
                
                    There is no standard staging system for central nervous system atypical teratoid/rhabdoid tumor.
                    The extent or spread of cancer is usually described as stages. There is no standard staging system for central nervous system atypical teratoid/rhabdoid tumor.    For treatment, this tumor is grouped as newly diagnosed or recurrent. Treatment depends on the following:         - The age of the child.    - How much cancer remains after surgery to remove the tumor.        Results from the following procedure are also used to plan treatment:         -   Ultrasound exam: A procedure in which high-energy sound waves (ultrasound) are bounced off internal tissues or organs, such as the kidney, and make echoes. The echoes form a picture of body tissues called a sonogram. The picture can be printed to be looked at later. This procedure is done to check for tumors that may also have formed in the kidney.
Question: what research (or clinical trials) is being done for Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor ?
Answer: New types of treatment are being tested in clinical trials.
                    This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.     Targeted therapy     Targeted therapy is a type of treatment that uses drugs or other substances to attack specific cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Targeted therapy is being studied in the treatment of recurrent childhood central nervous system atypical teratoid/rhabdoid tumor.
                
                
                    Patients may want to think about taking part in a clinical trial.
                    For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.   Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.   Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
                
                
                    Patients can enter clinical trials before, during, or after starting their cancer treatment.
                    Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.   Clinical trials are taking place in many parts of the country. See the Treatment Options section that follows for links to current treatment clinical trials. These have been retrieved from NCI's listing of clinical trials.
Question: What is (are) Retinoblastoma ?
Answer: Key Points
                    - Retinoblastoma is a disease in which malignant (cancer) cells form in the tissues of the retina.    - Retinoblastoma occurs in heritable and nonheritable forms.     -  Treatment for both forms of retinoblastoma should include genetic counseling.    - Children with a family history of retinoblastoma should have eye exams to check for retinoblastoma.     - A child who has heritable retinoblastoma has an increased risk of trilateral retinoblastoma and other cancers.    - Signs and symptoms of retinoblastoma include "white pupil" and eye pain or redness.     - Tests that examine the retina are used to detect (find) and diagnose retinoblastoma.    - Certain factors affect prognosis (chance of recovery) and treatment options.
                
                
                    Retinoblastoma is a disease in which malignant (cancer) cells form in the tissues of the retina.
                    The retina is the nerve tissue that lines the inside of the back of the eye. The retina senses light and sends images to the brain by way of the optic nerve.      Although retinoblastoma may occur at any age, it occurs most often in children younger than 2 years. The cancer may be in one eye (unilateral) or in both eyes (bilateral). Retinoblastoma rarely spreads from the eye to nearby tissue or other parts of the body.    Cavitary retinoblastoma is a rare type of retinoblastoma in which cavities (hollow spaces) form within the tumor.
                
                
                    Treatment for both forms of retinoblastoma should include genetic counseling.
                    Parents should receive genetic counseling (a discussion with a trained professional about the risk of genetic diseases) to discuss genetic testing to check for a mutation (change) in the RB1 gene. Genetic counseling also includes a discussion of the risk of retinoblastoma for the child and the child's brothers or sisters.
Question: Is Retinoblastoma inherited ?
Answer: Retinoblastoma occurs in heritable and nonheritable forms.
                    A child is thought to have the heritable form of retinoblastoma when one of the following is true:         - There is a family history of retinoblastoma.    - There is a certain mutation (change) in the RB1 gene. The mutation in the RB1 gene may be passed from the parent to the child or it may occur in the egg or sperm before conception or soon after conception.    - There is more than one tumor in the eye or there is a tumor in both eyes.    - There is a tumor in one eye and the child is younger than 1 year.        After heritable retinoblastoma has been diagnosed and treated, new tumors may continue to form for a few years. Regular eye exams to check for new tumors are usually done every 2 to 4 months for at least 28 months.    Nonheritable retinoblastoma is retinoblastoma that is not the heritable form. Most cases of retinoblastoma are the nonheritable form.
                
                
                    Treatment for both forms of retinoblastoma should include genetic counseling.
                    Parents should receive genetic counseling (a discussion with a trained professional about the risk of genetic diseases) to discuss genetic testing to check for a mutation (change) in the RB1 gene. Genetic counseling also includes a discussion of the risk of retinoblastoma for the child and the child's brothers or sisters.
                
                
                    Children with a family history of retinoblastoma should have eye exams to check for retinoblastoma.
                    A child with a family history of retinoblastoma should have regular eye exams beginning early in life to check for retinoblastoma, unless it is known that the child does not have the RB1 gene change. Early diagnosis of retinoblastoma may mean the child will need less intense treatment.   Brothers or sisters of a child with retinoblastoma should have regular eye exams by an ophthalmologist until age 3 to 5 years, unless it is known that the brother or sister does not have the RB1 gene change.
                
                
                    A child who has heritable retinoblastoma has an increased risk of trilateral retinoblastoma and other cancers.
                    A child with heritable retinoblastoma has an increased risk of a pineal tumor in the brain. When retinoblastoma and a brain tumor occur at the same time, it is called trilateral retinoblastoma. The brain tumor is usually diagnosed between 20 and 36 months of age. Regular screening using MRI (magnetic resonance imaging) may be done for a child thought to have heritable retinoblastoma or for a child with retinoblastoma in one eye and a family history of the disease. CT (computerized tomography) scans are usually not used for routine screening in order to avoid exposing the child to ionizing radiation.    Heritable retinoblastoma also increases the child's risk of other types of cancer such as lung cancer, bladder cancer, or melanoma in later years. Regular follow-up exams are important.